Aarey Drugs and Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?

Aarey Drugs and Pharmaceuticals share price is trading close to its 52-week high of Rs 100, with Aarey Drugs share price near Rs 95 on the NSE, nearly double its 52-week low of Rs 50.31. Given a recent profit decline alongside flagged governance compliance issues, this article presents these details plainly before laying out a balanced view on whether the stock is a buy, a hold, or a sell.

This Aarey Drugs stock analysis walks through the Q1 FY27 numbers, the flagged compliance matters, valuation against the pharma API sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.

Click Here – Get Free Investment Predictions

About Aarey Drugs and Pharmaceuticals

Keep this backdrop in mind when reading the rest of this Aarey Drugs share price review. Before deciding on Aarey Drugs share price, it helps to understand the underlying business. Aarey Drugs and Pharmaceuticals Ltd. manufactures active pharmaceutical ingredients (API) and bulk drugs, including products such as Metformin HCL, Mefenamic Acid and Doxophylline, serving pharmaceutical formulation manufacturers and merchant exporters.

Incorporated in 1990, the company has an established manufacturing history in API and bulk drugs, though its FY26 secretarial compliance report flagged several SEBI regulatory compliance gaps, a governance matter that investors should factor into their assessment alongside the company's financial performance.

Aarey Drugs and Pharmaceuticals Share Price Today: Key Levels

This snapshot is the starting point for any Aarey Drugs share price discussion. The table below summarises where Aarey Drugs share price stands right now against its recent trading range and market value.

Metric	Value
Aarey Drugs CMP (NSE)	Rs 95.38
Aarey Drugs CMP (BSE)	Rs 95.66
52-Week High	Rs 100.00
52-Week Low	Rs 50.31
Market Capitalisation	Approximately Rs 212 crore

Aarey Drugs share price is trading close to its 52-week high, nearly double its 52-week low, even as the most recent quarter's profit declined and governance compliance matters have been flagged.

Check the Univest Screener for Live Stock Data

Aarey Drugs and Pharmaceuticals Financial Performance

Track this line item closely if you are following Aarey Drugs share price closely. The Aarey Drugs share price trend is closely tied to how these numbers evolve each quarter. Aarey Drugs reported Q1 FY27 (June 2026 quarter) revenue of approximately Rs 46.34 crore, with net profit of Rs 1.02 crore, down 25.55 percent year on year. This followed the company's best-ever quarterly revenue and profit in the preceding March 2026 quarter, so the year-on-year decline should be read against that unusually strong prior base.

The company's FY26 secretarial compliance report, reviewed by the board on May 30, 2026, noted multiple SEBI non-compliances, including issues around warrant disclosure and related party transaction filing delays, alongside associated penalties, a matter investors should factor into their assessment of the company's governance practices.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	approximately Rs 46.34 crore	Rs 1.02 crore	Profit -25.55% YoY, against an unusually strong prior quarter

Valuation Check: Is Aarey Drugs and Pharmaceuticals Share Price Expensive?

It is one of the clearest signals available on Aarey Drugs share price today. Any view on Aarey Drugs share price should start from these valuation multiples. Aarey Drugs share price currently reflects a price to earnings ratio of about 70.3 times trailing earnings, a rich premium to the broader pharma API sector average of roughly 51.2 times. The price to book ratio stands near 1.8 times, with return on equity at a modest 2.64 to 3.13 percent depending on the period measured.

Debt to equity of 0.33 is moderate. Given the low return on equity alongside a rich PE multiple, and the flagged compliance matters, investors should weigh whether the current valuation is fully justified by the underlying fundamentals or reflects other market factors.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Aarey Drugs share price. Aarey Drugs share price is currently positioned close to its 52-week high of Rs 100 and nearly double its 52-week low of Rs 50.31, reflecting a strong overall run over the past year despite the recent quarterly profit decline and flagged governance matters. A stock trading this close to its high amid a profit dip and compliance flags warrants closer scrutiny of the drivers behind the price action.

Trading volumes remain moderate, so investors should track Aarey Drugs share price alongside any updates on the flagged compliance matters and continued quarterly performance, rather than reacting to the price action alone at these levels.

Download the Univest iOS App or Univest Android App to track Aarey Drugs' live price and technical levels.

Shareholding Pattern

Shifts here can influence Aarey Drugs share price more than headline news on some sessions. Aarey Drugs and Pharmaceuticals is a promoter-led API and bulk drugs manufacturer, with promoter holding at 37.7 percent, which has decreased modestly in the most recent quarter. A detailed current FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Aarey Drugs and Pharmaceuticals

• Established API manufacturing history: Incorporated in 1990, Aarey Drugs has a long operating history manufacturing active pharmaceutical ingredients and bulk drugs.
• Recent best-ever quarterly performance: The March 2026 quarter reflected the company's best-ever quarterly revenue and profit, showing capability for strong results under the right conditions.
• Product portfolio meeting international standards: Products meeting IP, BP, CP and USP standards support the company's ability to serve international pharmaceutical customers.

Risks and Factors to Watch

• Flagged SEBI compliance issues: The company's FY26 secretarial compliance report noted multiple SEBI non-compliances, including warrant disclosure and related party filing delays, alongside penalties, a governance matter deserving careful attention.
• Recent quarterly profit decline: Q1 FY27 profit fell 25.55 percent year on year, following an unusually strong prior quarter.
• Low return on equity: A return on equity of just 2.64 to 3.13 percent is modest, raising questions about capital efficiency at the company's current rich valuation.
• Rich valuation relative to fundamentals: A 70.3x PE against a low ROE and recent profit decline leaves limited room for disappointment.

Aarey Drugs and Pharmaceuticals Share Price Target: What the Data Suggests

Until then, Aarey Drugs share price remains best tracked through live, verified data rather than a single fixed number. Aarey Drugs does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Given the flagged compliance matters, investors should approach any price target with particular caution.

Investors considering this stock should review the company's compliance disclosures directly and track the Univest Screener, and should consult a SEBI-registered investment adviser given both the governance matters and the rich valuation involved.

Aarey Drugs and Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?

There is no shortcut here: Aarey Drugs share price needs to be judged against your own plan. This is the core question behind Aarey Drugs share price right now. The Aarey Drugs buy or sell decision should weigh the flagged governance matters carefully alongside the recent financial performance.

The case for buying: Investors who have independently reviewed the compliance matters and are satisfied with the company's remediation, and who see the API manufacturing business as fundamentally sound, may consider a position.

The case for holding: Existing shareholders who already track these compliance matters may prefer to stay invested while monitoring for resolution.

The case for waiting: Investors prioritising strong governance track records may prefer to wait for clearer resolution of the flagged compliance issues before investing.

Given the governance matters flagged here, weigh this carefully and consult a SEBI-registered investment adviser if unsure.

Conclusion

In short, Aarey Drugs share price calls for weighing these points together rather than in isolation. Aarey Drugs and Pharmaceuticals share price reflects an established API manufacturer trading near its 52-week high despite a recent profit decline and flagged SEBI compliance issues in its FY26 secretarial report. Whether that makes the stock a buy, a hold or a sell right now depends significantly on how you weigh those governance matters. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Aarey Drugs a good stock to buy right now?

Ans. Aarey Drugs trades near its 52-week high despite Q1 FY27 profit falling 25.55 percent year on year and a FY26 secretarial compliance report flagging multiple SEBI non-compliances. Investors should weigh these governance matters carefully alongside the company's API manufacturing fundamentals.

Q2. What compliance issues has Aarey Drugs faced?

Ans. Aarey Drugs' FY26 secretarial compliance report, reviewed by the board on May 30, 2026, flagged multiple SEBI non-compliances including issues around warrant disclosure and related party transaction filing delays, alongside associated penalties.

Q3. What is the Aarey Drugs share price today?

Ans. Aarey Drugs and Pharmaceuticals share price is trading around Rs 95 on the NSE, close to its 52-week high of Rs 100. The stock's 52-week low is Rs 50.31.

Q4. What is the Aarey Drugs share price target?

Ans. Aarey Drugs does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Given the flagged compliance matters, investors should consult a SEBI-registered adviser.

Q5. What does Aarey Drugs manufacture?

Ans. Aarey Drugs and Pharmaceuticals manufactures active pharmaceutical ingredients and bulk drugs, including Metformin HCL, Mefenamic Acid and Doxophylline, serving pharmaceutical formulation manufacturers.

Q6. What is Aarey Drugs' market capitalisation and PE ratio?

Ans. Aarey Drugs has a market capitalisation of approximately Rs 212 crore and trades at a price to earnings ratio of about 70.3 times, a rich premium to the pharma API sector average PE of roughly 51.2 times.